Investors of Aquestive Therapeutics Urged to Review Class Action Lawsuit Updates
In a significant development for shareholders of Aquestive Therapeutics, Inc. (NASDAQ AQST), law firm Robbins LLP has alerted stockholders about the ongoing class action lawsuit against the pharmaceutical company. This class action concerns investors who purchased or acquired AQST securities between June 16, 2025, and January 8, 2026.
According to Robbins LLP, the problem stems from allegations that Aquestive Therapeutics created a misleading narrative regarding the approval status of its drug Anaphylm. During the stipulated class period, it was reported that investors were led to believe that the company’s New Drug Application (NDA) for Anaphylm was likely to receive approval by the crucial Prescription Drug User Fee Act (PDUFA) date of January 31, 2026. However, an FDA communication revealed significant deficiencies in the NDA, stalling any discussions on labeling or commitments necessary for approval.
On January 9, 2026, the situation escalated when Aquestive announced to its shareholders that it had received a letter from the FDA indicating that the review process was not complete, and this delay would push the approval of Anaphylm far beyond the expected date. As a result of this disclosure, the company's stock price plummeted by more than 37%, plummeting from a closing price of $6.21 on January 8 to just $3.91 the following day.
The implications of this class action are significant for those affected. Shareholders who purchased or acquired Aquestive securities during the defined period may be eligible to take part in the lawsuit as lead plaintiffs or class members. Lead plaintiffs serve as representatives for the larger group of affected investors throughout the litigation process. Even those who choose not to engage directly with the lawsuit are entitled to any potential recovery that results from it. Shareholders are encouraged to contact Robbins LLP to explore their options further.
Robbins LLP operates on a contingency fee basis; thus, shareholders will incur no fees or expenses unless the firm secures a recovery on their behalf. This model allows investors to pursue legal avenues without fear of financial burdens.
Founded in 2002, Robbins LLP is a respected leader in shareholder rights litigation, dedicated to assisting investors in recovering losses and holding companies accountable for any wrongdoing. The firm has built a reputation for ensuring that corporate governance is upheld, making it a reliable partner for investors concerned about their rights and investments.
If you believe you are eligible to participate in the class action against Aquestive Therapeutics, reach out to Robbins LLP for expert guidance and representation. For ongoing updates and information regarding potential settlements, investors can also subscribe to Stock Watch, which keeps shareholders alerted about corporate misconduct and investor rights developments.
In these turbulent times, staying informed is key. Investors are encouraged to act quickly and take advantage of this opportunity to potentially recover losses arising from the misleading actions of Aquestive Therapeutics regarding Anaphylm.
Background of the Case
According to Robbins LLP, the problem stems from allegations that Aquestive Therapeutics created a misleading narrative regarding the approval status of its drug Anaphylm. During the stipulated class period, it was reported that investors were led to believe that the company’s New Drug Application (NDA) for Anaphylm was likely to receive approval by the crucial Prescription Drug User Fee Act (PDUFA) date of January 31, 2026. However, an FDA communication revealed significant deficiencies in the NDA, stalling any discussions on labeling or commitments necessary for approval.
The Disclosure
On January 9, 2026, the situation escalated when Aquestive announced to its shareholders that it had received a letter from the FDA indicating that the review process was not complete, and this delay would push the approval of Anaphylm far beyond the expected date. As a result of this disclosure, the company's stock price plummeted by more than 37%, plummeting from a closing price of $6.21 on January 8 to just $3.91 the following day.
What Does This Mean for Shareholders?
The implications of this class action are significant for those affected. Shareholders who purchased or acquired Aquestive securities during the defined period may be eligible to take part in the lawsuit as lead plaintiffs or class members. Lead plaintiffs serve as representatives for the larger group of affected investors throughout the litigation process. Even those who choose not to engage directly with the lawsuit are entitled to any potential recovery that results from it. Shareholders are encouraged to contact Robbins LLP to explore their options further.
No Financial Risk to Shareholders
Robbins LLP operates on a contingency fee basis; thus, shareholders will incur no fees or expenses unless the firm secures a recovery on their behalf. This model allows investors to pursue legal avenues without fear of financial burdens.
About Robbins LLP
Founded in 2002, Robbins LLP is a respected leader in shareholder rights litigation, dedicated to assisting investors in recovering losses and holding companies accountable for any wrongdoing. The firm has built a reputation for ensuring that corporate governance is upheld, making it a reliable partner for investors concerned about their rights and investments.
Next Steps
If you believe you are eligible to participate in the class action against Aquestive Therapeutics, reach out to Robbins LLP for expert guidance and representation. For ongoing updates and information regarding potential settlements, investors can also subscribe to Stock Watch, which keeps shareholders alerted about corporate misconduct and investor rights developments.
In these turbulent times, staying informed is key. Investors are encouraged to act quickly and take advantage of this opportunity to potentially recover losses arising from the misleading actions of Aquestive Therapeutics regarding Anaphylm.
Topics Financial Services & Investing）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.